Adagio is developing broadly-neutralizing monoclonal antibodies for the treatment of COVID-19 and other coronavirus infections. The company was created in July 2020 as a spin out of Adimab, a leading antibody discovery company that has discovered and optimized over 40 antibodies that have been progressed into clinical trials by its industry partners. Adagio’s antibodies have been designed to target SARS-CoV-2, the virus that causes COVID-19, in a way that provides potent anti-viral activity against all known forms of the virus. ADG20, the company’s lead asset, is an intramuscular injection that is being developed both as a treatment for COVID-19, as well as a preventive therapy after exposure to SARS-CoV-2. We believe that Adagio will generate a pipeline of broadly-neutralizing antibodies capable of treating future pandemic coronaviruses.
Bain Capital Healthcare
We have built one of the largest and deepest healthcare investing teams in the world. Click here to read more about the breadth and legacy of our efforts.